Serotonin Syndrome: Clinical Trials

8 trials for Serotonin Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 terminated, 1 unknown. 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 38Completed 4, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Serotonin Syndrome: new trials by email Literature Review of Serotonin Syndrome trials Research Report on Serotonin Syndrome

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid
Phase 3Active not recruitingCrinetics Pharmaceuticals Inc.1412025-11-192026-10-15
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
Cyproheptadine Hydrochloride 4 MG - Viral Pneumonia, Serotonin Syndrome
Phase 3UnknownCiusss de L'Est de l'Île de Montréal2002021-04-102021-04-02
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease
Phase 3WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2020-04-012020-02-05
Telotristat Etiprate for Carcinoid Syndrome Therapy
Telotristat etiprate, Placebo - Carcinoid Syndrome
Phase 3CompletedLexicon Pharmaceuticals762014-03-112018-02-26
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Telotristat etiprate - Carcinoid Syndrome
Phase 3CompletedLexicon Pharmaceuticals1242014-01-142019-09-17
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Telotristat etiprate, Placebo-matching telotristat etiprate - Carcinoid Syndrome
Phase 3CompletedLexicon Pharmaceuticals1352013-01-082018-02-27
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Lanreotide, Placebo - Carcinoid Syndrome
Phase 3CompletedIpsen1152009-05-012022-10-14
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) - Malignant Carcinoid Syndrome
Phase 3TerminatedIpsen42004-07-012020-04-30

Narrower conditions

Carcinoid Tumor (2)  ·  Neuroendocrine Tumors (2)  ·  COVID-19 (1)  ·  Carcinoid Heart Disease (1)  ·  Carcinoid Tumors, Intestinal (1)  ·  Diarrhea (1)  ·  Flushing (1)  ·  Malignant Carcinoid Syndrome (1)  ·  Pneumonia, Viral (1)

Broader conditions

Chemically-Induced Disorders (8)  ·  Drug-Related Side Effects and Adverse Reactions (8)  ·  Adenocarcinoma (4)  ·  Carcinoma (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Germ Cell and Embryonal (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Neuroectodermal Tumors (4)  ·  Carcinoid Tumor (2)  ·  Neuroendocrine Tumors (2)  ·  Cardiovascular Diseases (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)

Interventions

telotristat (3)  ·  lanreotide (2)  ·  Cyproheptadine (1)  ·  Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1)  ·  Standard of Care (1)  ·  telotristat ethyl (1)

Sponsors

Lexicon Pharmaceuticals (3)  ·  Ipsen (2)  ·  Ciusss de L'Est de l'Île de Montréal (1)  ·  Crinetics Pharmaceuticals Inc. (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)

Countries

United States (6)  ·  Belgium (4)  ·  France (4)  ·  Germany (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Canada (3)  ·  Israel (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Sweden (3)  ·  Brazil (2)  ·  Poland (2)  ·  Argentina (1)

Top investigators

Pablo Lapuerta, MD (3)  ·  Angela Lamarca (1)  ·  Juan Valle (1)

Results publications

PMID 32146619, PMID 34598813, PMID 27214300, PMID 29330194, PMID 29724499, PMID 30477789, PMID 31655936, PMID 31754316, PMID 32157590, PMID 33940581

NIH funding

2004 (1)